Molecular imaging research on 18F-FDG PET/CT and biomarker analysis to predict the efficacy of neoadjuvant camrelizumab combined with chemotherapy for resectable stage IIIA-IIIB NSCLC. Dual analysis ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback